Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.

被引：0
|
作者：
Schmoll, HJ
Tabernero, J
Nowacki, M
Maroun, J
Figer, A
Price, T
Lim, R
van Cutsem, E
Haller, D
Braud, F
机构：
[1] Univ Halle Wittenberg, Halle An Der Saale, K1Y 4K7, Germany
[2] Vall Hebron Univ Hosp, Barcelona, Spain
[3] Marie Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[4] Ottawa Reg Canc Ctr, Ottawa 117548, ON, Canada
[5] Tel Aviv Canc Ctr, B-3000 Tel Aviv, Israel
[6] Queen Elizabeth Hosp, Adelaide, SA 19104, Australia
[7] Natl Univ Singapore Hosp, Singapore, Singapore
[8] Univ Hosp Gasthuisberg, Louvain, Belgium
[9] Univ Penn, Philadelphia, PA USA
[10] Inst Europeo Oncol, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：251S / 251S
页数：1
相关论文
共 50 条
  • [1] Final safety findings from a randomized phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.
    Schmoll, H. J.
    Tabernero, J.
    Nowacki, M.
    Maroun, J.
    Price, T.
    Lim, R.
    Van Cutsem, E.
    De Braud, F.
    Haller, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 163S - 163S
  • [2] Capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer: Final safety findings from a randomized phase III trial
    Schmoll, H.
    Tabernero, J.
    Nowacki, M.
    Maroun, J.
    Price, T.
    Lim, R.
    Van Cutsem, E.
    de Braud, F.
    Haller, D.
    ANNALS OF ONCOLOGY, 2006, 17 : 25 - 26
  • [3] Initial safety findings from XELOXA: a randomised phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer
    Schmoll, H.
    Tabernero, J.
    Nowacki, M.
    Maroun, J.
    Price, T.
    Lim, R.
    Van Cutsem, E.
    de Braud, F.
    Haller, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 174 - 174
  • [4] First efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study)
    Hailer, D.
    Tabernero, J.
    Maroun, J.
    de Braud, F.
    Price, T.
    Van Cutsem, E.
    Hill, M.
    Gilberg, F.
    Rittweger, K.
    Schmoll, H.
    EJC SUPPLEMENTS, 2009, 7 (03): : 4 - 4
  • [5] Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer.
    Twelves, C
    Wong, A
    Nowacki, M
    McKendrick, J
    van Hazel, G
    Douillard, JY
    Díaz-Rubio, E
    Cassidy, J
    Maroun, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 251S - 251S
  • [6] EFFICACY FINDINGS FROM A RANDOMISED PHASE III TRIAL OF CAPECITABINE plus OXALIPLATIN VS. BOLUS 5-FU/LV FOR STAGE III COLON CANCER (NO16968): NO IMPACT OF AGE ON DISEASE-FREE SURVIVAL
    Haller, D.
    Cassidy, J.
    Tabernero, J.
    Maroun, J.
    De Braud, F.
    Price, T.
    Van Cutsem, E.
    Hill, M.
    Gilberg, F.
    Schmoll, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
  • [7] Positive efficacy results of the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer
    McKendrick, Joseph
    Cassidy, James
    Van Hazel, Guy
    Twelves, Chris
    Wong, Alfred
    Nowacki, Marek
    Kroning, Hendrik
    Cervantes, Andres
    Herrmann, Richard
    Burris, Howard, III
    ANNALS OF ONCOLOGY, 2004, 15 : 73 - 74
  • [8] Initial safety findings from a phase III study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC)
    Bennouna, J.
    Liedo, G.
    Ychou, M.
    Conroy, T.
    Hebbar, M.
    Adenis, A.
    Paillot, B.
    Faroux, R.
    Douillard, J.
    Ducreux, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 179 - 180
  • [9] TP, TS AND DPD AS POTENTIAL PREDICTORS OF OUTCOME FOLLOWING CAPECITABINE PLUS OXALIPLATIN (XELOX) VS. BOLUS 5-FLUOROURACIL/LEUCOVORIN (5-FU/LV) AS ADJUVANT THERAPY FOR STAGE III COLON CANCER: UPDATED BIOMARKER FINDINGS FROM STUDY NO16968 (XELOXA)
    Schmoll, H.
    Tabernero, J.
    Maroun, J. A.
    De Braud, F.
    Price, T.
    Van Cutsem, E.
    Hill, M.
    Hoersch, S.
    Rittweger, K.
    Haller, D.
    ANNALS OF ONCOLOGY, 2012, 23 : 187 - 187
  • [10] COST COMPARISON: CAPECITABINE plus OXALIPLATIN (XELOX) VS 5-FU/LV plus OXALIPLATIN (FOLFOX4) IN THE ADJUVANT TREATMENT OF PATIENTS WITH COLON CANCER (ACC)
    Winterhalder, R.
    Delmore, G.
    Hardegger, T.
    Urspruch, A.
    Hieke, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 201 - 202
12345